These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 26855682)

  • 1. Mavoglurant in adolescents with fragile X syndrome: analysis of Clinical Global Impression-Improvement source data from a double-blind therapeutic study followed by an open-label, long-term extension study.
    Bailey DB; Berry-Kravis E; Wheeler A; Raspa M; Merrien F; Ricart J; Koumaras B; Rosenkranz G; Tomlinson M; von Raison F; Apostol G
    J Neurodev Disord; 2016; 8():1. PubMed ID: 26855682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials.
    Berry-Kravis E; Des Portes V; Hagerman R; Jacquemont S; Charles P; Visootsak J; Brinkman M; Rerat K; Koumaras B; Zhu L; Barth GM; Jaecklin T; Apostol G; von Raison F
    Sci Transl Med; 2016 Jan; 8(321):321ra5. PubMed ID: 26764156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mavoglurant in Fragile X Syndrome: Results of two open-label, extension trials in adults and adolescents.
    Hagerman R; Jacquemont S; Berry-Kravis E; Des Portes V; Stanfield A; Koumaras B; Rosenkranz G; Murgia A; Wolf C; Apostol G; von Raison F
    Sci Rep; 2018 Nov; 8(1):16970. PubMed ID: 30451888
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients.
    Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C
    Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome.
    Heussler H; Cohen J; Silove N; Tich N; Bonn-Miller MO; Du W; O'Neill C; Sebree T
    J Neurodev Disord; 2019 Aug; 11(1):16. PubMed ID: 31370779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arbaclofen in fragile X syndrome: results of phase 3 trials.
    Berry-Kravis E; Hagerman R; Visootsak J; Budimirovic D; Kaufmann WE; Cherubini M; Zarevics P; Walton-Bowen K; Wang P; Bear MF; Carpenter RL
    J Neurodev Disord; 2017; 9():3. PubMed ID: 28616094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults.
    Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J
    Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
    Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modafinil in children and adolescents with attention-deficit/hyperactivity disorder: a preliminary 8-week, open-label study.
    Boellner SW; Earl CQ; Arora S
    Curr Med Res Opin; 2006 Dec; 22(12):2457-65. PubMed ID: 17257460
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of mavoglurant on visual attention and pupil reactivity while viewing photographs of faces in Fragile X Syndrome.
    Hessl D; Harvey D; Sansone S; Crestodina C; Chin J; Joshi R; Hagerman RJ; Berry-Kravis E
    PLoS One; 2019; 14(1):e0209984. PubMed ID: 30653533
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
    Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
    Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
    Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
    Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trial.
    Mischoulon D; Witte J; Levy M; Papakostas GI; Pet LR; Hsieh WH; Pencina MJ; Ward S; Pollack MH; Fava M
    J Clin Psychiatry; 2012 Mar; 73(3):353-7. PubMed ID: 21939613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship of ADHD symptoms and global illness severity in adults treated with lisdexamfetamine dimesylate.
    Weisler RH; Babcock T; Adeyi B; Brams M
    Postgrad Med; 2014 Sep; 126(5):31-41. PubMed ID: 25295648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluvoxamine CR in the long-term treatment of social anxiety disorder: the 12- to 24-week extension phase of a multicentre, randomized, placebo-controlled trial.
    Stein DJ; Westenberg HG; Yang H; Li D; Barbato LM
    Int J Neuropsychopharmacol; 2003 Dec; 6(4):317-23. PubMed ID: 14604447
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Desvenlafaxine 50 mg/d Versus Placebo in the Long-Term Treatment of Major Depressive Disorder: A Randomized, Double-Blind Trial.
    Boyer P; Vialet C; Hwang E; Tourian KA
    Prim Care Companion CNS Disord; 2015; 17(4):. PubMed ID: 26693033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
    Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
    Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjunctive zonisamide therapy in the long-term treatment of children with partial epilepsy: results of an open-label extension study of a phase III, randomized, double-blind, placebo-controlled trial.
    Guerrini R; Rosati A; Bradshaw K; Giorgi L
    Epilepsia; 2014 Apr; 55(4):568-78. PubMed ID: 24621319
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.